Key Segmentation
By Radioisotope Type
-
Lutetium-177 (Lu-177)
-
Gallium-68 (Ga-68)
-
Fluorine-18 (F-18)
-
Actinium-225 (Ac-225)
-
Others
By Service Type
-
Process Development
-
Analytical & Quality Control Testing
-
Clinical Manufacturing
-
Commercial Manufacturing
-
Fill-Finish & Packaging
By Application
-
Oncology
-
Neurology
-
Cardiology
-
Theranostics
-
Others
By End User
-
Pharmaceutical Companies
-
Biotechnology Companies
-
Academic & Research Institutes
-
Nuclear Medicine Centers
-
Hospitals & Healthcare Systems
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Radiopharmaceutical CDMO Market was valued at USD 3.27 billion in 2025.
The market is projected to reach USD 8.14 billion by 2035.
The market is expected to expand at a CAGR of 9.54% during the forecast period.
Lutetium-177 (Lu-177) accounted for the largest revenue share of 29.00% in 2025 owing to increasing commercialization of targeted radio ligand therapies and theranostic treatment approaches.
North America dominated the global market owing to its advanced nuclear medicine infrastructure, increasing radio ligand therapy adoption, and strong presence of pharmaceutical and biotechnology companies.